A Move to Bispecific Antibodies: From Research to Clinical Application
Improved antibody production and recombinant techniques have fueled the development of antibodies and antibody constructs. Bispecific antibodies (bsAbs) are a versatile class of targeted therapeutics designed to bind two different sites, which can be either two different epitopes on the same antigen or located on two antigens. The clinical therapeutic effects of bsAbs are superior to those of monoclonal antibodies (mAbs), with broad applications for tumor immunotherapy as well as for the treatment of other diseases. The high-throughput Octet® BLI platform allows for rapid screening of cell lines expressing the target bsAb – label-free, fluidics-free and in real-time. This Application Guide provides insight into solutions from our customers working in the field of engineering bsAb as next generation therapeutics. We hope that this can stimulate new ideas for the development and improvement of current clinical strategies.
